🇺🇸 FDA

Company profile · Sponsor

Roche

Roche Registration Limited

E280026 · EMA pharma GB
Pipeline
24
Drugs
0
Patents
0

Quick answer

Roche (E280026) is a pharma company. headquartered in GB. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E280026
Exchange EMA
Company type pharma
Headquarters GB

Pipeline (24)

Search pipeline →

  1. A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB AS MONOTHERAPY OR IN ADDITION TO BASELINE THERAPY IN PATIENTS WITH MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD)

    Roche

    Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

    phase 3 other active

    1 trial

  2. A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (BFAST: Blood First Assay Screening Trial)

    Roche

    Advanced or metastatic Non-small cell lung cancer (NSCLC)

    phase 3 other active

    1 trial

  3. A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sclerosis

    Roche

    Primary Progressive Multiple Sclerosis (PPMS)

    phase 3 other active

    1 trial

  4. A Phase III, Randomized, Double-Blind Study of Tiragolumab Plus Atezolizumab Compared with Placebo Plus Atezolizumab in Participants with Completely Resected Stage IIB, IIIA, or Select IIIB, PD-L1 Positive, Non-Small Cell Lung Cancer who have received Adjuvant Platinum-Based Chemotherapy

    Roche

    Non-Small Cell Lung Cancer

    phase 3 other active

    1 trial

  5. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Basket Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis

    Roche

    NMDAR or LGI1 mediated autoimmune Encephalitis

    phase 3 other active

    1 trial

  6. A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with previously treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer

    Roche

    KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

    phase 3 other active

    1 trial

  7. A Two-Part, Seamless, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Patients With Spinal Muscular Atrophy

    Roche

    Spinal Muscular Atrophy (SMA)

    phase 3 other active

    1 trial

  8. Alecensa 150 mg hard capsules, IMFINZI 50 mg/mL concentrate for solution for infusion.

    Roche

    Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  9. Alecensa 150 mg hard capsules, VINORELBINE, Gemcitabin-GRY 1000 mg Pulver zur Herstellung einer Infusionslösung, Carboplatin-GRY® 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin ACTAVIS 10 mg/ml concentrat pentru soluţie perfuzabilă, ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Alecensa 150 mg hard capsules

    Roche

    Completely resected, Stage Ib (tumors ≥ 4 cm) to Stage IIIa, Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  10. Amyvid 1900 MBq/mL solution for injection, VIZAMYL 400 MBq/mL solution for injection, Amyvid 800 MBq/mL solution for injection, VIZAMYL 400 MBq/mL solution for injection, Trontinemab, Placebo Trontinemab, Amyvid 800 MBq/mL solution for injection, Neuraceq 300 MBq/mL solution for injection, Amyvid 1900 MBq/mL solution for injection, [18F]MK-6240

    Roche

    Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia due to AD)

    phase 3 small molecule active

    1 trial

  11. CARBOPLATIN, GEMCITABINE, PEMETREXED, Sindaxel 6 mg/ml concentrat pentru soluţie perfuzabilă, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CISPLATIN, Abraxane 5 mg/ml powder for dispersion for infusion., RO 749-9790/F02-02

    Roche

    RET fusion−positive, metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  12. CellCept 500 mg film-coated tablets, CellCept 1 g/5 ml powder for oral suspension, Gazyvaro 1,000 mg concentrate for solution for infusion., CellCept 500 mg film-coated tablets

    Roche

    Childhood Idiopathic Nephrotic Syndrome

    phase 3 small molecule active

    1 trial

  13. Crovalimab

    Roche

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  14. Crovalimab, Crovalimab

    Roche

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  15. Crovalimab, ECULIZUMAB, Crovalimab

    Roche

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  16. ECULIZUMAB, Crovalimab, Crovalimab

    Roche

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  17. GEMCITABINE , Tecentriq, PEMETREXED , VINORELBINE , CISPLATIN , DOCETAXEL , Tecentriq 1,200 mg concentrate for solution for infusion

    Roche

    Non−Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  18. Gazyva Placebo, Gazyvaro 1,000 mg concentrate for solution for infusion.

    Roche

    Systemic Lupus Erythematosus (SLE)

    phase 3 small molecule active

    1 trial

  19. Gazyvaro 1,000 mg concentrate for solution for infusion., Chlorambucil 2 mg tablets, Fasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion., Venclexta, Venclyxto, Venclexta, Venclyxto, Venclexta, Venclyxto

    Roche

    Chronic Lymphocytic Leukemia (CLL)

    phase 3 small molecule active

    1 trial

  20. Gazyvaro 1,000 mg concentrate for solution for infusion., Prograf 1 mg Hartkapseln, Prograf 0,5 mg Hartkapseln, Prograf 5 mg Hartkapseln

    Roche

    Primary Membranous Nephropathy (pMN)

    phase 3 small molecule active

    1 trial

  21. Hemlibra 150 mg/mL solution for injection, Hemlibra 30 mg/mL solution for injection

    Roche

    Hemophilia A

    phase 3 small molecule active

    1 trial

  22. Hemlibra 150 mg/mL solution for injection, Hemlibra 30 mg/mL solution for injection

    Roche

    Mild or moderate hemophilia A without FVIII inhibitors

    phase 3 small molecule active

    1 trial

  23. Herceptin 150 mg powder for concentrate for solution for infusion, Perjeta 420 mg concentrate for solution for infusion

    Roche

    Solid Malignant Tumors

    phase 3 small molecule active

    1 trial

  24. IBRANCE 125 mg film-coated tablets, Placebo Giredestrant, IBRANCE 100 mg hard capsules, RO7197597, Placebo Letrozole, IBRANCE 75 mg hard capsules, IBRANCE 75 mg film-coated tablets, IBRANCE 125 mg hard capsules, Femara® 2,5 mg Filmtabletten, IBRANCE 100 mg film-coated tablets

    Roche

    ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is Roche?

Roche (E280026) is a pharma company. headquartered in GB. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Roche sponsor?

We track 24 ClinicalTrials.gov-linked programs for Roche, including A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB AS MONOTHERAPY OR IN ADDITION TO BASELINE THERAPY IN PATIENTS WITH MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD) and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Roche company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.